-
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| ISIN | US76135L1017 |
| Beta | 0.24 |
|---|---|
| Market Cap | 3M |
| PE Ratio | None |
| Target Price | 170.725 |
| Dividend Yield | None |
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for REVB using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025